The pathological myocardial hypertrophy associated with hypertension contains the seed for further maladaptive development. Increased myocardial oxygen consumption, impaired epicardial coronary perfusion, ventricular fibrosis and remodelling, abnormalities in long-axis function and torsion, cause, to a varying degree, a mixture of systolic and diastolic abnormalities. In addition, chronotropic incompetence and peripheral factors such as lack of vasodilator reserve and reduced arterial compliance further affect cardiac output particularly on exercise. Many of these factors are common to hypertensive heart failure with a normal ejection fraction as well as systolic heart failure. There is increasing evidence that these apparently separate phenotypes are part of a spectrum of heart failure differing only in the degree of ventricular remodelling and volume changes. Furthermore, dichotomizing heart failure into systolic and diastolic clinical entities has led to a paucity of clinical trials of therapies for heart failure with a normal ejection fraction. Therapies aimed at reversing myocardial fibrosis, and targets outside the heart such as enhancing vasodilator reserve and improving chronotropic incompetence deserve further study and may improve the exercise capacity of hypertensive heart failure patients. Hypertension heart disease with heart failure is simply not a dysfunction of systole and diastole. Other peripheral factors including heart rate and vasodilator response with exercise may deserve equal attention in an attempt to develop more effective treatments for this disorder.
Introduction
High blood pressure, including pre-hypertension, is a major global health economic issue, accounting for about half of the total cases of stroke and ischaemic heart disease. It is responsible for about 7.6 million deaths each year and costs over 92 million disability-adjusted life years, both of which represent 13.5 and 6.0% of the respective global total in the year 2001. Low-income and middle-income countries, predominantly in eastern Europe, east and south Asia (China and India) and the Pacific regions, shoulder about 80% of the cardiovascular disease burden, half of which is in people of working age. 1 The failing heart in hypertensive heart disease (HHD) may present as predominant heart failure with normal ejection fraction (HFNEF) or systolic heart failure (SHF) and contributes significant morbidity and mortality. It represents a chain of pathological events starting with ageing and atherosclerosis, left ventricular hypertrophy (LVH), coronary artery disease with or without myocardial infarction, to finally heart failure and end-stage heart disease. This cardiovascular disease continuum, by which common and overlapping pathophysiological mechanisms are involved in multiple steps in disease development across the entire spectrum of cardiovascular disease as well as diseases of other target organs, including the brain and kidneys, has received experimental and clinical validation, with an increasing recognition of the important roles of oxidative stress and nitric oxide synthase, metalloproteinases and their inhibitors, renin-angiotensin-aldosterone system and sympathetic nervous system, in the development of heart failure. [2] [3] [4] [5] A number of primary prevention trials demonstrated that treating hypertension can reduce the development of heart failure up to 50%. In patients with left ventricular systolic dysfunction 6 or LVH, control of blood pressure prevents or retards ventricular remodelling and decreases the incidence of overt heart failure. 7 In patients with established heart failure, further decreases of blood pressure with therapy may lower the mortality rate, slow the progression of disease, reduce the number of hospitalizations and exacerbations, and enhance quality of life and functional capacity. 8 About half of the patients with symptoms of heart failure have a normal ejection fraction. HFNEF is common among female elderly patients with a history of hypertension or atrial fibrillation and has an adverse prognosis similar to that of SHF. [9] [10] [11] [12] There is currently no evidence of the superiority of specific antihypertensive drugs in HHD presenting with HFNEF. 13, 14 Though a simple diuretic may be as efficacious as a combination with angiotensinogen-converting enzyme inhibitor or angiotensin receptor antagonist in relieving symptoms and improving submaximal exercise capacity, there is still a lack of convincing evidence of modern pharmacological heart failure therapy that improves prognosis in patients with HFNEF, and further clinical trial results are pending. 15 , 16 The inefficacy of modern heart failure therapy on survival in patients with HFNEF was also emphasized by large epidemiological surveys, which observed an improved prognosis over the last two decades in patients with SHF, but not in patients with HFNEF. 9 Furthermore, there is still no general consensus that HFNEF and SHF are two distinct heart failure phenotypes, 17 or just a precursor stage of SHF, [18] [19] [20] and that the role of systolic function in HFNEF is still a matter of debate. [17] [18] [19] [21] [22] [23] [24] [25] [26] We will review the pathophysiology underlying the progression of HHD to congestive heart failure, in particular the functional and morphological changes in both types of heart failure.
Cardiac hypertrophy
The current view of HHD is that it first leads to increased cardiac hypertrophy, a maladaptive process required to normalize wall stress and to maintain cardiac output. 27 It occurs in response to an increase in systolic blood pressure and, therefore, ventricular loading throughout the ejection period due to a combination of increased proximal aortic stiffening and augmentation of late systolic pressure from early return of pulse wave reflection that is commonly associated with ageing. 28, 29 A high baseline left ventricular mass value in initially normotensive patients predicts subsequent increases in blood pressure and the development of hypertension, independent of other risk factors. 30 The LVH results in prolonged ejection period at the expense of reduction of diastole at any given heart rate and causes delayed myocardial relaxation. The decreased diastolic blood pressure from aortic stiffening and a reduced LV filling time with or without rise in LV filling pressure may compromise coronary perfusion. 31, 32 The increased myocardial oxygen demand from a combination of raised systolic blood pressure, LVH and prolonged ejection time in addition to compromised coronary perfusion predisposes hypertensive patients to coronary ischaemia, which may be further jeopardized in those with a pre-existing coronary artery disease. 33 LVH is a strong predictor of cardiovascular morbidity and mortality, regardless of blood pressure values or the presence of other cardiovascular risk factors.
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Ventricular fibrosis
Biomechanical stretch and neurohumoral factors induce changes in intracellular signalling pathways, resulting in an increased protein synthesis and activation of specific genes promoting cardiomyocyte growth, eventually leading to left ventricular remodelling and cardiac dysfunction. [38] [39] [40] Ventricular remodelling describes structural changes in the LV in response to chronic alterations in volume overload or pressure loads. The remodelling process results from alterations in cardiac myocytes as well as the extracellular matrix, including fibroblasts and several different types of macromolecules, for example, type I and III collagen, elastin and fibronectin. Unlike in athletic training, there is a disproportionate growth of the extracellular matrix and increased modification and enhancement of perivascular and interstitial (perimysial) collagen mass, in addition to the development of endothelial dysfunction, increasing vulnerability of the ventricle to myocardial ischaemia, dysfunction, heart failure, arrhythmia and sudden death. 41 Abnormalities in the extent and distribution of collagen within the remodelling heart have been recognized as playing an important role in the pathogenesis of heart failure. The collagen homoeostasis is determined by the rate and extent of synthesis and degradation.
Carboxy-terminal propeptide procollagen type I (PICP), a breakdown product in a 1:1 stoichiometric ratio to fibrillar collagen type I that accounts for 85-90% of myocardial collagen, can be measured from serum and reflect fibrogenesis. 42 Type III collagen accounts for the majority of the remaining myocardial collagen. Amino-terminal propeptide procollagen type III (PIIINP), an extension peptide that cleaved off from the procollagen type III in the conversion to collagen type III, can also be measured in the serum. However, in contrast to PICP, amino-terminal propeptide procollagen type III is not completely removed from its procollagen precursor during the extracellular processing and as a result, serum PICP may reflect fibrogenesis better than serum amino-terminal propeptide procollagen type III. Collagen degradation is under the control of matrix metalloproteinases (MMPs), a family of zinc-dependent interstitial enzymes, and their tissue inhibitors (TIMPs). Commonly measured serum markers of myocardial collagen turnover include gelatinases (MMP-2 and -9), collagenase (MMP-13), tissue inhibitors of MMPs (TIMP-1 and -2) and carboxy-terminal telopeptide of collagen type I, a breakdown product of collagen type I. 43 Several reports have provided important new insights into patients with HHD who present with SHF or heart failure with normal ejection fraction (HFNEF). Querejeta et al. 44 demonstrated a positive correlation between coronary sinus and peripheral serum levels of PICP and these correlated well with myocardial accumulation of fibrillar collagen type I assessed histologically. Moreover, there was a progressive significant increase in PICP levels from normal control individuals, HHD patients without heart failure, to hypertensive heart failure patients with variable ejection fractions. In addition to elevated PICP and amino-terminal propeptide procollagen type III, patients with HFNEF may also show serologic evidence of an active fibrotic process in terms of collagen turnover or MMP activities (carboxy-terminal telopeptide of collagen type I, MMP-2 and -9), which corresponds with the severity of diastolic dysfunction. 45 Ahmed et al. 46 have demonstrated normal MMP/TIMP profiles in hypertensive patients with normal LV structure and ejection fraction, and elevated serum levels of TIMP-1 and MMP-9 in those with LVH and HFNEF. A TIMP-1 level 41200 ng ml À1 predicted the presence of LVH with HFNEF (specificity 88%; positive predictive value of 94% with area under the receiver operator curve of 0.71). Lopez et al. 47 found that mysial collagen that is related to muscle compartments was reduced in SHF patients but that perivascular and scar-related collagen volumes were higher in both SHF and HFNEF hypertensive patients than in normotensive individuals and in SHF compared with HFNEF patients. Thus, in HHD, an increase in interstitial collagen is associated with HFNEF, whereas a degradation of endo-and perimysial components of the collagen scaffolding is accompanied by muscle fibre slippage, thinning of myocardium, spherical dilation of ventricular chamber and the development of SHF with a reduced LV ejection fraction. These morphological findings in the SHF hypertensive group were associated with an increased protein expression of MMP-1 relative to TIMP-1 in tissue and blood when compared with control individuals and HFNEF patients, which also correlated directly with LV end-diastolic diameter and inversely with LV ejection fraction. 47 Thus, patterns of collagen deposition differ between SHF and HFNEF. An imbalance in the MMP-1/TIMP-1 ratio may herald LV dilation and reduced EF in SHF. In future, serum measurements of MMP and TIMP levels may be used to detect abnormalities in the extracellular matrix of the heart that could account for ventricular remodelling and dysfunction in hypertensive patients, and these markers might also serve to monitor interventions designed to alter the remodelling process. 48 
Patterns of hypertrophic remodelling
In addition to the above, the pattern of hypertrophic remodelling is relevant. Three major patterns of LV remodelling are recognized: concentric remodelling, eccentric hypertrophy and that due to a myocardial infarction, which is a combination of the other two patterns, when the distended and dilated infarct tissue increases the LV volume with a combined volume and pressure overload on the non-infarct areas. 5 Under pressure overload, as in hypertension, remodelling is essentially concentric by adding sarcomeres in parallel to achieve an increased cardiomyocyte thickness, and is characterized by nondilated, thick-walled LV. 49 Thus, the LV wall thickness increases more than the LV cavity volume; as a result, the relative wall thickness (normally p0.42) and the ratio of the LV mass to the enddiastolic volume increase. Earlier prospective studies have demonstrated that hypertension-related concentric remodelling is associated with adverse cardiovascular outcomes, including myocardial infarction, heart failure and increased mortality. 35, [50] [51] [52] [53] Despite normal LV ejection fraction and unchanged endocardial stress-shortening relationship in concentric LVH, a subtle systolic dysfunction can be demonstrated by depressed LV midwall fractional shortening on traditional two-dimensional echocardiography [51] [52] [53] [54] and tagged cardiac magnetic resonance 55 and, more recently, abnormalities of LV long and short axes by tissue Doppler and strain echocardiography. [56] [57] [58] In contrast, eccentric remodelling is associated with volume overload and involves the addition of sarcomeres in series to achieve myocyte lengthening. There is a proportional increase in LV mass and volume, so that the ventricle becomes dilated, with normal relative wall thickness but reduced LV systolic function. Eccentric hypertrophy has been found to be associated with worse systolic function in a subgroup of patients with hypertension. 59 The difference in the hypertrophic remodelling between HFNEF and SHF hypertensive patients correlates with distinct patterns of peptide growth factor induction in both conditions. 60 In addition, HFNEF is characterized by cardiomyocyte hypertrophy and preserved myofilamentary density, whereas SHF by minimal cardiomyocyte hypertrophy and loss of myofilaments. 60 In addition, the resting tension of isolated cardiomyocytes is higher in HFNEF. 61, 62 This may be related to an increased interstitial collagen with lack of change in the MMP-1/TIMP-1 ratio and a higher ratio of shorter (stiffer) N2B isoform to longer (more compliant) N2BA titin isoform, a giant sarcomeric cytoskeletal protein that extends from the Z-lines to the centre of the thick filament and functions as a molecular spring, contributing to the high resting passive stiffness of the myocardium 63, 64 and perhaps to the higher restoring forces and preservation of untwisting of the LV (see below). 65 Does HHD evolve as concentric LVH with HFNEF and transition to SHF with LV dilation and reduced EF?
Although it has been recognized clinically that occasional patients who present with typical SHF have only hypertension as a possible aetiology and this is especially common where coronary artery disease is uncommon and treatment of hypertension is poor such as in Africa and parts of Asia, there is little information on whether patients with hypertension and LVH can progress to heart failure with LV dilatation and it has been disputed whether this does occur in the absence of ischaemic heart disease (see Figure 1) . Recently, additional clinical insights into the transition from concentric LVH to failure have been provided by two recently completed longitudinal studies using serial echocardiography and one cross-sectional multiethnic study using cardiac magnetic resonance imaging with tagging. 66 In a retrospective cohort of 159 predominantly middle-aged hypertensive African Americans with concentric LVH and a normal LV ejection fraction, only 18% developed a reduced LV ejection fraction after a follow-up of about 4 years. Moreover, nearly half of those who did develop a low LVEF had an interval myocardial infarction. 67 In the Cardiovascular Health Study, it has been shown that increased baseline LV mass was an independent risk factor for the development of depressed ejection fraction 5 years later in elderly Caucasian individuals, independent of coronary artery disease or myocardial infarction. However, the majority of cases of LVH were of eccentric remodelling. Furthermore, concentric LVH was not an independent risk factor in multivariate analysis for the development of a low ejection fraction, possibly due to the small number of patients (n ¼ 26) with concentric LVH. 68 In 441 individuals without a known cardiovascular disease, Rosen et al. 69 demonstrated that LV systolic function, evaluated by midwall circumferential strain or LV ejection fraction by magnetic resonance imaging, decreased with increasing concentric remodelling (higher LV mass/volume ratio) in men. In women, circumferential strain was also declined in those with the highest quintile of LV mass/volume ratio, but there was no such association with LV ejection fraction. In both genders, the inverse association between regional strain and the LV mass/volume ratio was more pronounced in the left anterior descending artery territory, though this observation appeared inconsistent in women in multivariable analysis, and there was no significant association between septal or posterior LV thickness and regional LV strain. Nevertheless, the study suggests that there may be a subtle regional systolic dysfunction in response to concentric remodelling. 69 It might be possible that those in the highest quintile of the LV mass/volume ratio with reduced circumferential strain have been imaged during the transition from compensatory remodelling to overt SHF with dilated LV. Contrary to this notion, however, the LV volumes in this study were decreased in the highest quintile of LV mass/volume ratio, whereas LV volume is increased with LV failure. This finding was corroborated by Olmsted County database that observed an opposite evolution with progressive reduction in LV end-diastolic volumes in HHD as HFNEF develops. In addition, variable LV geometric patterns were observed and, despite traditional teaching, concentric LVH or remodelling is not invariably present in HFNEF. 70 Moreover, in hypertrophic cardiomyopathy, a disease also characterized by diastolic LV dysfunction, the evolution towards a dilated LV is only 3.5%. 71 Nevertheless, the time course of remodelling does depend to a certain extent on the aetiology. Sufficient myocardial necrosis from infarction or myocarditis is a potent stimulus for the initiation of the post-infarct remodelling process, in which stretched and dilated infarcted tissue increases LV volume with a combined volume and pressure load on non-infarcted areas, leading to LV dilation and a reduced ejection fraction, irrespective of whether there is pre-existing concentric remodelling. The time course and pattern of development of heart failure are therefore quicker after myocardial infarction, which is the commonest cause of SHF. In HHD, remodelling in the absence of myocardial necrosis is a slower process. 19 Initially, LV hypertrophy by itself leads to reduced systolic and diastolic function particularly in the long axis. Compensatory circumferential contraction and rotation normalize the ejection fraction (see below). However, at later stages, a further remodelling will occur, with resultant LV enlargement and development from HFNEF to more obvious SHF. 19 Serial longitudinal imaging studies are therefore much needed in future to clarify the progression of HHD to heart failure Figure 1 Hypertension and heart failure (adapted from Drazner 66 ).
and whether concentric LVH in the absence of myocardial infarction is a common pathway leading to SHF.
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Insights from traditional to translational echocardiography
There is still debate whether HFNEF and SHF are indeed distinct HF phenotypes. 18, 72 Communitybased epidemiology data suggest that compared with hypertensive or healthy control individuals, patients with HFNEF have a more impaired renal function, despite smaller end-diastolic volumes, lower cardiac output, higher end-diastolic pressures, and more vascular and ventricular systolic stiffening with increased diastolic stiffness. 70 A careful evaluation of echocardiographic data reveals that patients with HFNEF have accentuated LVH, more severe diastolic dysfunction and left atrial dilation or failure. 70, 73 Furthermore, HFNEF is frequently referred to as diastolic heart failure as slow LV relaxation and high LV stiffness were further confirmed from invasive haemodynamic studies. [74] [75] [76] [77] On the basis of the above data acquired at rest, three different pathophysiologic theories have been postulated for HFNEF. First, an increase in intrinsic muscle stiffness and impaired relaxation in diastole result in higher left atrial pressures to fill adequately, predisposing these patients to pulmonary venous congestion and dyspnoea especially on exertion. 74, 75, 77 Second, increased systolic ventricular and arterial stiffening, that is, deranged ventriculoarterial coupling, may contribute to the pathophysiology of HFNEF by exaggerating hypertensive response with increased systolic load and inducing load-dependent diastolic dysfunction especially during exercise or other stresses. 78 Third, an enhanced sensitivity to volume overload from increased LV remodelling and dilation with volumedependent elevation of filling pressures was observed by Maurer et al. 79 in a subgroup of hypertensive HFNEF patients from the Cardiovascular Health Study who had renal impairment and larger LV volumes but normal systolic ventricular and vascular stiffness. Thus, impaired renal function and renal arterial atherosclerosis in the elderly may also be involved in causing rapid rises in blood pressure and excessive fluid retention due to chronic activation of the renin-angiotensin-aldosterone system. These elevations, together with underlying diastolic dysfunction, are the causes of recurrent acute pulmonary oedema in these patients. Renal revascularization has been shown to decrease incidence of pulmonary oedema due to renal artery stenosis 80 and is likely the result of reduction of fluctuating hypertension and subsequent exacerbation of diastolic dysfunction. These different mechanisms proposed for HFNEF may have important implications for differing therapeutic strategies.
Although a global LV systolic performance is preserved, 17 HFNEF has reduced LV long-axis shortening 21 and depressed tissue Doppler myocardial systolic velocity. [21] [22] [23] [24] [25] [26] The success of cardiac resynchronization therapy has underscored the importance of dys-synchrony in the pathophysiology of SHF, independent of the QRS duration. 81 Interestingly, about 33-39% of HFNEF patients showed evidence of systolic dys-synchrony and 56-58% of them diastolic dys-synchrony at rest. [82] [83] Moreover, 25% of these patients demonstrated isolated systolic dys-synchrony, and the correlation between systolic and diastolic dys-synchrony was poor. 82 This was in contrast to the close curvilinear relationship between the absolute annulus systolic and early diastolic velocities seen in a range of cardiac diseases and normal individuals. 84 Systolic dyssynchrony in HFNEF is associated with reduced peak basal myocardial velocities, lower stroke work and even lower 'normal' ejection fraction than in those without it. 83 This suggests that systolic dyssynchrony contributes towards a wider spectrum of systolic dysfunction in HFNEF, casting doubt about the orthodox view that HFNEF is truly a clinical entity of diastolic dysfunction.
More recently, with the advent of strain echocardiography based on tissue Doppler 85 or speckledtracking technology, 86, 87 myocardial deformation in the longitudinal, radial and circumferential directions as well as torsion or twist can now be quantified, which was feasible earlier only in magnetic resonance imaging using tagging 88 or tissue phase-contrast velocity mapping. 89 Strain measures the extent of myocardial deformation and is free from effects of tethering and translation of adjacent myocardial segments that are associated with tissue Doppler velocities. 90 Speckle-tracking imaging based on two-dimensional automated frame-to-frame tracking (between 40 and 100 frames per s) of unique patterns of natural acoustic markers (speckles) on standard gray-scale B-mode images is independent of myocardial translation and angle dependency inherent to tissue Doppler-derived strain parameters. 91 Thus, strain echocardiography may have a clinical advantage over tissue Doppler velocities of better assessment of segmental and global myocardial contractility. 92 Interest in ventricular torsion has increased during the last two decades. Studies have suggested that the twist during the cardiac cycle is important for normal function, possibly contributing to the subsequent untwisting or suction that aids early diastolic filling, and the delay of which is associated with diastolic dysfunction and raised LV filling pressures in aortic stenosis. 93 Torsion helps normalize relatively uniform stresses, sarcomere length changes, and myocardial workload across the LV wall, and contributes to energy-efficient ejection. 94, 95 Speckle-tracking echocardiography offers torsional or 'twisting' motion assessment, derived from circumferential strain at different short-axis levels of the heart, which is promoted by the virtue of a single myofibre band forming a double helix in the LV, changing gradually from a right-handed helix in the subendocardium to a left-handed helix in the subepicardium. 96 Accordingly, LV torsion is defined as apical rotation relative to the base. The larger radius of subepicardial fibres generates higher torque that dominates the direction of the twist, causing rotation of the base and apex in clockwise and counterclockwise directions, respectively, when viewed from the apex. The LV untwisting predominantly occurs during isovolumetric relaxation and begins just slightly before aortic valve closure, followed in time by the peak intraventricular gradient, and then by long-axis lengthening and short-axis expansion that may precede or coincide with peak early diastolic filling. 97, 98 However, like many diastolic parameters, there are age-related degenerative changes in the LV torsion, with increased peak systolic twisting but reduction and delay in untwisting velocities. No gender differences were noted in peak twist or untwisting velocities. 99, 100 Another source of the restoring force that drives diastolic torsional recoil is systolic deformation within the sheet structure, the so-called shear strain, due to significant fibre shearing within the sheet planes during systole. 101 Measuring longitudinal or circumferential shear is another promising approach to the assessment of torsion with speckle tracking, allowing full assessment of overall deformation in addition to three-dimensional strains and investigation of regional differences in torsion. 102 Hypertension, like other progressive myocardial diseases for example, coronary artery disease and hypertrophic cardiomyopathy, preferentially affects subendocardial function and the longitudinal fibres running along it. 103 The epicardial function may remain relatively unaffected. Thus, in HFNEF, LV longitudinal and radial strains are reduced but circumferential strain and torsion, which reflect subepicardial function, are normal at least at rest. This transmural heterogeneity in myocardial contractile function with normal LV torsion and circumferential strain may be a compensatory mechanism for preserving the normal LV ejection fraction in these patients. 104 However, the untwisting, which is determined by preceding peak systolic twist and LV end-systolic volume, is delayed and reduced in parallel to the degree of LV hypertrophy in hypertension, 65 whereas untwisting is preserved but its onset is delayed in HFNEF. 105 These variable results should be clarified in further studies.
As the disease progresses, midwall and subepicardial myocardium are affected by pathological changes, including reduction of mysial collagen, eccentric remodelling and LV dilation. The LV circumferential strain, twisting and untwisting rates, in addition to longitudinal and radial strains, may be reduced in the later stages and in SHF. Thus, the relative differences in longitudinal and twisting mechanics may provide pathophysiological insights into the mechanism of LV dysfunction in HHD. The transmural gradient between subendocardial (longitudinal function) and epicardial (twisting function) fibres may provide an early detection of subclinical myocardial disease. 106 Non-diastolic and peripheral factors: the missing link between hypertension and HFNEF There is good evidence that arterial compliance is also associated with diastolic dysfunction. Mottram et al. 107 demonstrated that in hypertensive patients with exertional breathlessness, progressively abnormal diastolic function is associated with reduced arterial compliance and arterial stiffness was an independent predictor of diastolic dysfunction. Arterial stiffness is also linked to reduced coronary flow velocity reserve, which may be relevant to the development of subendocardial ischaemia and reduced longitudinal ventricular function. 108 However, most studies in this area are undertaken under resting conditions that demonstrate normal or nearnormal LV systolic performance but abnormal diastolic properties in hypertension or HFNEF. A reduced aortic distensibility has been reported in HFNEF and it correlated with exercise limitation. 109 Haemodynamic data obtained during exercise and other stresses may be key in differentiating HFNEF and hypertensive patients, though very few studies on the response to aerobic exercise have been reported in HFNEF and most have exclusively focused on LV and vascular function. An individual's exercise capacity depends not only on the cardiovascular function but also on the coordinated efforts and integrity of other major systems including pulmonary, neural, endocrine, haematological and skeletal muscle systems. In SHF, each system has major abnormalities, for example, the skeletal muscles, which exert significant impact on exercise intolerance independent of LV function. 110 If all components of the exercise response are taken into account, the LV abnormalities found in SHF, including diastolic dysfunction, increased passive stiffness and impaired systolic function, have only a modest role in determining exercise capacity, less than thought earlier. 111 Several investigators have reported that a significant number of HFNEF patients have attenuated heart rate response to exercise, similar to SHF patients. 77, [112] [113] [114] Furthermore, those with such chronotropic incompetence have an even more severe exercise intolerance than those without it. The slower heart rate rise, lower peak heart rate and impaired recovery suggest autonomic (parasympathetic) dysfunction. Contractile reserve is also impaired at peak exercise. It is worth noting that systemic vasodilation with exercise has been reported to be impaired in some, but not all, studies of HFNEF. 113, 115 Borlaug et al.
113
noted an impaired systemic vasodilation in 17 HFNEF patients during exercise, which accounted for the depressed cardiac output increase in addition to lower peak heart rate. There were no differences in exercise-induced cardiac preload rise, estimated lung congestion on radionuclide ventriculography or plasma catecholamines. In contrast, Hundley et al. 115 reported relatively preserved endothelial function by cardiac magnetic resonance assessment of flow-mediated dilation in the superficial femoral artery followed within 48 h by symptom-limited exercise in nine HFNEF elderly patients in the absence of advanced arteriosclerosis, diabetes or hypercholesterolaemia.
These data suggest that other non-diastolic peripheral factors, such as heart rate and vasodilator reserve, may also play a role in exercise intolerance in patients with HFNEF and challenge the notion that diastolic dysfunction alone primarily explains exercise-related symptoms in this disorder by limiting left ventricular end-diastolic volume and thus cardiac reserve. 112 It appears that the development of HFNEF depends on loss of compensatory systemic vasodilator and chronotropic reserve, in addition to other abnormalities, such as diastolic dysfunction and ventricular-arterial stiffening as mentioned above.
Clinical implications
From the maladaptive development of cardiac hypertrophy to detrimental consequences of increased myocardial oxygen consumption, impaired epicardial coronary perfusion, ventricular fibrosis and remodelling, abnormalities in long-axis function and torsion, there is clearly a mixture of varying degrees of systolic and diastolic abnormalities representing the same disease processes that evolve gradually as a continuum in HHD. Patients with HFNEF have similar, though not as severe, pathophysiologic characteristics compared with patients with typical SHF, including severely reduced exercise capacity (peak oxygen consumption and ventilatory anaerobic threshold), neuroendocrine activation (norepinephrine and B-type natriuretic peptide levels) and impaired quality of life. 116 In addition, chronotropic incompetence and lack of vasodilator and contractile reserves in addition to diastolic LV dysfunction, such as increase in intrinsic passive diastolic stiffness and evidence of raised LV filling pressure, are not unique to patients with HFNEF but also occur in SHF. Thus, classifying heart failure into systolic and diastolic heart failure on the basis of ejection fraction is somewhat misleading as it implies a primary or dominating mechanism to which therapy should be targeted. 113 It appears more useful to classify heart failure according to the aetiology and the mechanisms involved in the individual patient, which may be different. 19 Table 1 summarizes the similarities and differences between HFNEF and SHF and illustrates that increased ventricular volume, reflecting remodelling, is the main discrepancy.
Multimodal cardiovascular imaging, including resting and dynamic echocardiography, vascular assessments for arterial stiffness, carotid intimamedia thickness and endothelial dysfunction, may have a vital role in analysing these processes and uncovering the subtle morphological and physiological characteristics of this heterogeneous condition, and to guide active intervention for treatment and prevention. An emerging concept in the treatment of hypertension recognizes that progressive vascular damage can continue to occur even when blood pressure is controlled. It is conceivable that antihypertensive drugs with vascular modifying properties of attenuating or reversing age-associated vascular wall remodelling and arterial stiffening will be more preferable to those without it. 117, 118 Furthermore, dichotomizing heart failure into systolic and diastolic clinical entities potentially narrows our therapeutic focus. Given the disappointing results of recent clinical trials, these kind of approaches that target extra-cardiac factors may be more fruitful such as chronotropic incompetence with exercise training, [119] [120] pharmacologic interventions and/or selective, physiological pacing during exercise (cardiac resynchronization therapy may be one of the possible pacing modes). 111 Further investigation of treatments to enhance vasodilator reserve and their effectiveness in this population is also warranted. [121] [122] [123] [124] [125] In summary, HHD with heart failure is simply not a dysfunction of systole or diastole alone but to some extent involves both. In addition, other peripheral factors including heart rate, arterial compliance and vasodilator response with exercise deserve equal attention in an attempt to develop more effective treatments and prevention strategies.
Search strategy and selection criteria
We searched MEDLINE using 'hypertension' as the key word in combination with, 'heart failure', 'remodelling', 'pressure overload', 'volume overload' and 'echocardiography'. We searched all major cardiovascular journals: New England Journal of Medicine, The Lancet, Journal of the American Medical Association, Circulation, Journal American College of Cardiology, Heart and European Heart Journal for similar and related articles. Reference lists in key articles were searched to identify older publications. More than 200 articles were analysed.
